Menu utilisateur

Accès à distance ? S'identifier sur le proxy UCLouvain

Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications

Onglets principaux

Télécharger
  • Open access
  • PDF
  • 2.76 M
Mandarano, Martina Bellezza, Guido Belladonna, Maria Laura Van den Eynde, Benoît [UCL] Chiari, Rita Sidoni, Angelo

(eng) Several cancers, especially non-small cell lung cancer (NSCLC), are able to escape the immunosurveillance of tumor-infiltrating lymphocytes (TILs); among the molecules involved, the indoleamine 2,3-dioxygenase 1 (IDO-1) and the programmed cell death ligand-1 (PD-L1) play a crucial role. These aspects are of great interest in the current immunotherapeutic era, therefore the current study analyses the TILs, IDO-1, and PD-L1 interactions and their correlations with clinicopathological parameters and prognosis in NSCLC. One hundred ninety-three NSCLC surgical specimens, formalin-fixed, and paraffin-embedded were assessed for TILs density, TILs localization, IDO-1 (clone 4.16H1), and PD-L1 (clone E1L3N) immunohistochemical expressions. This data was correlated with clinicopathological parameters, disease free, and overall survivals. IDO-1 and PD-L1 high expressions were related to the solid pattern of adenocarcinomas (respectively p = 0.036 and p = 0.026); high PD-L1 expression was correlated with squamous histotype (p = 0.048). IDO-1 overexpression correlated with former smokers (p = 0.041), higher adenocarcinoma stages (p = 0.039), and with both higher TILs density and PD-L1 expression (respectively p = 0.025 and p = 0.0003). A better prognosis was associated with TILs intratumoral or mixed localizations (p = 0.029). TILs localization affects NSCLC prognosis; the higher expression of IDO-1 and PD-L1 in poorly differentiated and more aggressive lung adenocarcinomas, as well as the correlation between high PD-L1 expression and squamous cell histotype, confirm the more efficient immunoescaping of these NSCLC subgroups.

Type de document Article de périodique (Journal article) – Article de recherche
Type d'accès Accès libre
Année de publication 2019
Langue Anglais
Information sur le périodique "Virchows Archiv" - Vol. 474, no. 2, p. 159-168 (2019)
Peer reviewed oui
Editeur Springer International ((Germany) Berlin)
issn 0945-6317
e-issn 1432-2307
Statut de la publication Publié
Affiliations UCL - SSS/DDUV - Institut de Duve
UCL - SSS/DDUV/GECE - Génétique cellulaire
Mots-clés Pathology and Forensic Medicine ; Cell Biology ; Molecular Biology ; General Medicine
Liens
  1. Travis William D., Brambilla Elisabeth, Noguchi Masayuki, Nicholson Andrew G., Geisinger Kim R., Yatabe Yasushi, Beer David G., Powell Charles A., Riely Gregory J., Van Schil Paul E., Garg Kavita, Austin John H.M., Asamura Hisao, Rusch Valerie W., Hirsch Fred R., Scagliotti Giorgio, Mitsudomi Tetsuya, Huber Rudolf M., Ishikawa Yuichi, Jett James, Sanchez-Cespedes Montserrat, Sculier Jean-Paul, Takahashi Takashi, Tsuboi Masahiro, Vansteenkiste Johan, Wistuba Ignacio, Yang Pan-Chyr, Aberle Denise, Brambilla Christian, Flieder Douglas, Franklin Wilbur, Gazdar Adi, Gould Michael, Hasleton Philip, Henderson Douglas, Johnson Bruce, Johnson David, Kerr Keith, Kuriyama Keiko, Lee Jin Soo, Miller Vincent A., Petersen Iver, Roggli Victor, Rosell Rafael, Saijo Nagahiro, Thunnissen Erik, Tsao Ming, Yankelewitz David, International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma, 10.1097/jto.0b013e318206a221
  2. Gridelli Cesare, Ardizzoni Andrea , Barberis Massimo , Cappuzzo Federico , Casaluce Francesca , Danesi Romano , Troncone Giancarlo , De Marinis Filippo , Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology, 10.21037/tlcr.2017.05.09
  3. Thunnissen Erik, Allen Timothy Craig, Adam Julien, Aisner Dara L., Beasley Mary Beth, Borczuk Alain C., Cagle Philip T., Capelozzi Vera Luiza, Cooper Wendy, Hariri Lida P., Kern Izidor, Lantuejoul Sylvie, Miller Ross, Mino-Kenudson Mari, Radonic Teodora, Raparia Kirtee, Rekhtman Natasha, Roy-Chowdhuri Sinchita, Russell Prudence, Schneider Frank, Sholl Lynette M., Tsao Ming Sound, Vivero Marina, Yatabe Yasushi, Immunohistochemistry of Pulmonary Biomarkers: A Perspective From Members of the Pulmonary Pathology Society, 10.5858/arpa.2017-0106-sa
  4. Dunn Gavin P., Old Lloyd J., Schreiber Robert D., The Three Es of Cancer Immunoediting, 10.1146/annurev.immunol.22.012703.104803
  5. Anguille S., Smits E. L., Bryant C., Van Acker H. H., Goossens H., Lion E., Fromm P. D., Van Tendeloo V. F., Berneman Z. N., Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy, 10.1124/pr.114.009456
  6. D’Errico Gabriele, Machado Heather L., Sainz Bruno, A current perspective on cancer immune therapy: step-by-step approach to constructing the magic bullet, 10.1186/s40169-016-0130-5
  7. Brambilla Elisabeth, Le Teuff Gwénaël, Marguet Sophie, Lantuejoul Sylvie, Dunant Ariane, Graziano Stephen, Pirker Robert, Douillard Jean-Yves, Le Chevalier Thierry, Filipits Martin, Rosell Rafael, Kratzke Robert, Popper Helmut, Soria Jean-Charles, Shepherd Frances A., Seymour Lesley, Tsao Ming Sound, Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer, 10.1200/jco.2015.63.0970
  8. Ruffini Enrico, Asioli Sofia, Filosso Pier Luigi, Lyberis Paraskevas, Bruna Maria Cristina, Macrì Luigia, Daniele Lorenzo, Oliaro Alberto, Clinical Significance of Tumor-Infiltrating Lymphocytes in Lung Neoplasms, 10.1016/j.athoracsur.2008.10.067
  9. Zeng Dong-Qiang, Yu Yun-Fang, Ou Qi-Yun, Li Xiao-Yin, Zhong Ru-Zhi, Xie Chuan-Miao, Hu Qiu-Gen, Prognostic and predictive value of tumor-infiltrating lymphocytes for clinical therapeutic research in patients with non-small cell lung cancer, 10.18632/oncotarget.7282
  10. Levina Vera, Su Yunyun, Gorelik Elieser, Immunological and Nonimmunological Effects of Indoleamine 2,3-Dioxygenase on Breast Tumor Growth and Spontaneous Metastasis Formation, 10.1155/2012/173029
  11. Brochez Lieve, Chevolet Ines, Kruse Vibeke, The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy, 10.1016/j.ejca.2017.01.011
  12. Schalper Kurt A., Carvajal-Hausdorf Daniel, McLaughlin Joseph, Altan Mehmet, Velcheti Vamsidhar, Gaule Patricia, Sanmamed Miguel F., Chen Lieping, Herbst Roy S., Rimm David L., Differential Expression and Significance of PD-L1, IDO-1, and B7-H4 in Human Lung Cancer, 10.1158/1078-0432.ccr-16-0150
  13. Munn David H., Mellor Andrew L., Indoleamine 2,3 dioxygenase and metabolic control of immune responses, 10.1016/j.it.2012.10.001
  14. Munn David H, Blocking IDO activity to enhance anti-tumor immunity, 10.2741/e414
  15. Smith Courtney, Chang Mee Young, Parker Katherine H., Beury Daniel W., DuHadaway James B., Flick Hollie E., Boulden Janette, Sutanto-Ward Erika, Soler Alejandro Peralta, Laury-Kleintop Lisa D., Mandik-Nayak Laura, Metz Richard, Ostrand-Rosenberg Suzanne, Prendergast George C., Muller Alexander J., IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development, 10.1158/2159-8290.cd-12-0014
  16. Theate I., van Baren N., Pilotte L., Moulin P., Larrieu P., Renauld J.-C., Herve C., Gutierrez-Roelens I., Marbaix E., Sempoux C., Van den Eynde B. J., Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues, 10.1158/2326-6066.cir-14-0137
  17. Fallarino Francesca, Grohmann Ursula, Puccetti Paolo, Indoleamine 2,3-dioxygenase: From catalyst to signaling function : HIGHLIGHTS, 10.1002/eji.201242572
  18. Albini Elisa, Rosini Verdiana, Gargaro Marco, Mondanelli Giada, Belladonna Maria L., Pallotta Maria Teresa, Volpi Claudia, Fallarino Francesca, Macchiarulo Antonio, Antognelli Cinzia, Bianchi Roberta, Vacca Carmine, Puccetti Paolo, Grohmann Ursula, Orabona Ciriana, Distinct roles of immunoreceptor tyrosine-based motifs in immunosuppressive indoleamine 2,3-dioxygenase 1, 10.1111/jcmm.12954
  19. Tsao M-S., Le Teuff G., Shepherd F.A., Landais C., Hainaut P., Filipits M., Pirker R., Le Chevalier T., Graziano S., Kratze R., Soria J-C., Pignon J-P., Seymour L., Brambilla E., PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer, 10.1093/annonc/mdx003
  20. Yang Ching-Yao, Lin Mong-Wei, Chang Yih-Leong, Wu Chen-Tu, Yang Pan-Chyr, Programmed cell death-ligand 1 expression is associated with a favourable immune microenvironment and better overall survival in stage I pulmonary squamous cell carcinoma, 10.1016/j.ejca.2015.12.033
  21. Callea M, Pedica F, Doglioni C (2016) Programmed death 1 (PD-1) and its ligand (PD-L1) as a new frontier in cancer immunotherapy and challenges for pathologist: state of the art. Pathologica 108(2):48–58
  22. Ilie M., Long-Mira E., Bence C., Butori C., Lassalle S., Bouhlel L., Fazzalari L., Zahaf K., Lalvée S., Washetine K., Mouroux J., Vénissac N., Poudenx M., Otto J., Sabourin J. C., Marquette C. H., Hofman V., Hofman P., Comparative study of the PD-L1 status between surgically resected specimens and matched biopsies of NSCLC patients reveal major discordances: a potential issue for anti-PD-L1 therapeutic strategies, 10.1093/annonc/mdv489
  23. Herbst Roy S, Baas Paul, Kim Dong-Wan, Felip Enriqueta, Pérez-Gracia José L, Han Ji-Youn, Molina Julian, Kim Joo-Hang, Arvis Catherine Dubos, Ahn Myung-Ju, Majem Margarita, Fidler Mary J, de Castro Gilberto, Garrido Marcelo, Lubiniecki Gregory M, Shentu Yue, Im Ellie, Dolled-Filhart Marisa, Garon Edward B, Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial, 10.1016/s0140-6736(15)01281-7
  24. Teng Michele W.L., Ngiow Shin Foong, Ribas Antoni, Smyth Mark J., Classifying Cancers Based on T-cell Infiltration and PD-L1, 10.1158/0008-5472.can-15-0255
  25. Ferdinande L, Decaestecker C, Verset L, Mathieu A, Moles Lopez X, Negulescu A-M, Van Maerken T, Salmon I, Cuvelier C A, Demetter P, Clinicopathological significance of indoleamine 2,3-dioxygenase 1 expression in colorectal cancer, 10.1038/bjc.2011.513
  26. Soliman Hatem, Rawal Bhupendra, Fulp Jimmy, Lee Ji-Hyun, Lopez Alexis, Bui Marylin M., Khalil Farah, Antonia Scott, Yfantis Harris G., Lee Dong H., Dorsey Tiffany H., Ambs Stefan, Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry, 10.1007/s00262-013-1393-y
  27. Jacquemier Jocelyne, Bertucci François, Finetti Pascal, Esterni Benjamin, Charafe-Jauffret Emmanuelle, Thibult Marie-Laure, Houvenaeghel Gilles, Van den Eynde Benoit, Birnbaum Daniel, Olive Daniel, Xerri Luc, High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma, 10.1002/ijc.25979
  28. Kim Jin Won, Nam Kyung Han, Ahn Sang-Hoon, Park Do Joong, Kim Hyung-Ho, Kim Se Hyun, Chang Hyun, Lee Jeong-Ok, Kim Yu Jung, Lee Hye Seung, Kim Jee Hyun, Bang Soo-Mee, Lee Jong Seok, Lee Keun-Wook, Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer, 10.1007/s10120-014-0440-5
  29. Cooper Wendy A., Tran Thang, Vilain Ricardo E., Madore Jason, Selinger Christina I., Kohonen-Corish Maija, Yip PoYee, Yu Bing, O’Toole Sandra A., McCaughan Brian C., Yearley Jennifer H., Horvath Lisa G., Kao Steven, Boyer Michael, Scolyer Richard A., PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma, 10.1016/j.lungcan.2015.05.007
  30. Sun Jong-Mu, Zhou Wei, Choi Yoon-La, Choi So-Jung, Kim Se Eun, Wang Zhen, Dolled-Filhart Marisa, Emancipator Kenneth, Wu Dianna, Weiner Russell, Frisman D., Kim Hong Kwan, Choi Yong Soo, Shim Young Mog, Kim Jhingook, Prognostic Significance of PD-L1 in Patients with Non–Small Cell Lung Cancer: A Large Cohort Study of Surgically Resected Cases, 10.1016/j.jtho.2016.04.007
  31. Sorensen SF, Zhou W, Dolled-Filhart M, Georgsen JB, Wang Z, Emancipator K, Wu D, Busch-Sørensen M, Meldgaard P, Hager H (2016) PD-L1 expression and survival among patients with advanced non-small cell lung cancer treated with chemotherapy. Transl Oncol 9(1):64–69. https://doi.org/10.1016/10.1016/j.tranon.2016.01.003
  32. Chen Y, Mu C, Huang J (2012) Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study. Tumori 98(6):751–755. https://doi.org/10.1700/1217.13499
  33. Kim Moon-Young, Koh Jaemoon, Kim Sehui, Go Heounjeong, Jeon Yoon Kyung, Chung Doo Hyun, Clinicopathological analysis of PD-L1 and PD-L2 expression in pulmonary squamous cell carcinoma: Comparison with tumor-infiltrating T cells and the status of oncogenic drivers, 10.1016/j.lungcan.2015.01.016
  34. Wang A., Wang H.Y., Liu Y., Zhao M.C., Zhang H.J., Lu Z.Y., Fang Y.C., Chen X.F., Liu G.T., The prognostic value of PD-L1 expression for non-small cell lung cancer patients: A meta-analysis, 10.1016/j.ejso.2015.01.020
  35. McLaughlin Joseph Francis, Schalper Kurt, Carvajal-Hausdorf Daniel E., Velcheti Vamsidhar, Haack Herbert, Silver Matthew, Goldberg Sarah B., Herbst Roy S., Rimm David L., Domain-specific PD-L1 protein measurement in non-small cell lung cancer (NSCLC)., 10.1200/jco.2014.32.15_suppl.8064
  36. Naito Y, Saito K, Shiiba K, Ohuchi A, Saigenji K, Nagura H, Ohtani H (1998) CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res 58(16):3491–3494
  37. Salgado R., Denkert C., Demaria S., Sirtaine N., Klauschen F., Pruneri G., Wienert S., Van den Eynden G., Baehner F. L., Penault-Llorca F., Perez E. A., Thompson E. A., Symmans W. F., Richardson A. L., Brock J., Criscitiello C., Bailey H., Ignatiadis M., Floris G., Sparano J., Kos Z., Nielsen T., Rimm D. L., Allison K. H., Reis-Filho J. S., Loibl S., Sotiriou C., Viale G., Badve S., Adams S., Willard-Gallo K., Loi S., The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014, 10.1093/annonc/mdu450
  38. Astigiano Simonetta, Morandi Barbara, Costa Roberta, Mastracci Luca, D'Agostino Antonella, Ratto Giovanni Battista, Melioli Giovanni, Frumento Guido, Eosinophil Granulocytes Account for Indoleamine 2,3-Dioxygenase-Mediated Immune Escape in Human Non Small Cell Lung Cancer, 10.1593/neo.04658
  39. Parra Edwin Roger, Villalobos Pamela, Zhang Jiexin, Behrens Carmen, Mino Barbara, Swisher Stephen, Sepesi Boris, Weissferdt Annika, Kalhor Neda, Heymach John Victor, Moran Cesar, Zhang Jianjun, Lee Jack, Rodriguez-Canales Jaime, Gibbons Don, Wistuba Ignacio I., Immunohistochemical and Image Analysis-Based Study Shows That Several Immune Checkpoints are Co-expressed in Non–Small Cell Lung Carcinoma Tumors, 10.1016/j.jtho.2018.03.002
  40. Volaric Ashley, Gentzler Ryan, Hall Richard, Mehaffey James H., Stelow Edward B., Bullock Timothy N., Martin Linda W., Mills Anne M., Indoleamine-2,3-Dioxygenase in Non–Small Cell Lung Cancer : A Targetable Mechanism of Immune Resistance Frequently Coexpressed With PD-L1, 10.1097/pas.0000000000001099
  41. Brunnström Hans, Johansson Anna, Westbom-Fremer Sofia, Backman Max, Djureinovic Dijana, Patthey Annika, Isaksson-Mettävainio Martin, Gulyas Miklos, Micke Patrick, PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability, 10.1038/modpathol.2017.59
  42. The Positive Relationship Between γH2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma, 10.21873/invivo.11221
  43. Driver Brandon R., Miller Ross A., Miller Tara, Deavers Michael, Gorman Blythe, Mody Dina, Ge Yimin, Barrios Roberto, Bernicker Eric, Kim Min, Cagle Philip T., Programmed Death Ligand-1 (PD-L1) Expression in Either Tumor Cells or Tumor-Infiltrating Immune Cells Correlates With Solid and High-Grade Lung Adenocarcinomas, 10.5858/arpa.2017-0028-oa
  44. Xie Q, Wang L, Zhu B, Wang Y, Gu J, Chen Z (2008) The expression and significance of indoleamine -2,3-dioxygenase in non small cell lung cancer cell. Zhongguo Fei Ai Za Zhi 11(1):115–119. https://doi.org/10.3779/j.issn.1009-3419.2008.01.025
  45. Tumeh Paul C., Harview Christina L., Yearley Jennifer H., Shintaku I. Peter, Taylor Emma J. M., Robert Lidia, Chmielowski Bartosz, Spasic Marko, Henry Gina, Ciobanu Voicu, West Alisha N., Carmona Manuel, Kivork Christine, Seja Elizabeth, Cherry Grace, Gutierrez Antonio J., Grogan Tristan R., Mateus Christine, Tomasic Gorana, Glaspy John A., Emerson Ryan O., Robins Harlan, Pierce Robert H., Elashoff David A., Robert Caroline, Ribas Antoni, PD-1 blockade induces responses by inhibiting adaptive immune resistance, 10.1038/nature13954
  46. Galon J., Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome, 10.1126/science.1129139
  47. Hiraoka K, Miyamoto M, Cho Y, Suzuoki M, Oshikiri T, Nakakubo Y, Itoh T, Ohbuchi T, Kondo S, Katoh H, Concurrent infiltration by CD8+ T cells and CD4+ T cells is a favourable prognostic factor in non-small-cell lung carcinoma, 10.1038/sj.bjc.6602934
  48. Lin Gen, Fan Xirong, Zhu Weifeng, Huang Cheng, Zhuang Wu, Xu Haipeng, Lin Xiandong, Hu Dan, Huang Yunjian, Jiang Kan, Miao Qian, Li Chao, Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer, 10.18632/oncotarget.20233
  49. Gaule Patricia, Smithy James W., Toki Maria, Rehman Jamaal, Patell-Socha Farah, Cougot Delphine, Collin Philippe, Morrill Paul, Neumeister Veronique, Rimm David L., A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1, 10.1001/jamaoncol.2016.3015
  50. Rimm David L., Han Gang, Taube Janis M., Yi Eunhee S., Bridge Julia A., Flieder Douglas B., Homer Robert, West William W., Wu Hong, Roden Anja C., Fujimoto Junya, Yu Hui, Anders Robert, Kowalewski Ashley, Rivard Christopher, Rehman Jamaal, Batenchuk Cory, Burns Virginia, Hirsch Fred R., Wistuba Ignacio I., A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non–Small Cell Lung Cancer, 10.1001/jamaoncol.2017.0013
  51. McLaughlin Joseph, Han Gang, Schalper Kurt A., Carvajal-Hausdorf Daniel, Pelekanou Vasiliki, Rehman Jamaal, Velcheti Vamsidhar, Herbst Roy, LoRusso Patricia, Rimm David L., Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer, 10.1001/jamaoncol.2015.3638
Référence bibliographique Mandarano, Martina ; Bellezza, Guido ; Belladonna, Maria Laura ; Van den Eynde, Benoît ; Chiari, Rita ; et. al. Assessment of TILs, IDO-1, and PD-L1 in resected non-small cell lung cancer: an immunohistochemical study with clinicopathological and prognostic implications. In: Virchows Archiv, Vol. 474, no. 2, p. 159-168 (2019)
Permalien http://hdl.handle.net/2078.1/213633